Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus By: Autolus Therapeutics plc via GlobeNewswire October 17, 2023 at 07:00 AM EDT LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024. The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus By: Autolus Therapeutics plc via GlobeNewswire October 17, 2023 at 07:00 AM EDT LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024. The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com
LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024. The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com